Table 4. Baseline measurements and post-treatment quality of life with the EORTC QLQ-30 and Br-23 questionnaires and the Anxiety as State and as Trait with the STAI questionnaire. A Coruña, Spain, 2013-2015.
| Baseline | Post-treatment | Difference | p | |||||
| n | Mean±SD* | n | Mean±SD* | |||||
| EORTC QLQ C-30 | ||||||||
| Global Health Status | 181 | 69,2 ±21,1 | 181 | 72,0 ±21,6 | 2,7 ±23,4 | 0,167 | ||
| Functional scales | ||||||||
| Physical function | 185 | 92,3 ±12,4 | 185 | 84,6 ±16,3 | -7,7 ±15,1 | <0,001 | ||
| Role function | 182 | 93,3 ±14,3 | 182 | 85,4 ±22,2 | -7,9 ±23,3 | <0,001 | ||
| Emotional function | 183 | 63,0 ±25,0 | 183 | 74,4 ±23,7 | 11,3 ±25,2 | <0,001 | ||
| Cognitive Function | 183 | 84,5 ±18,2 | 183 | 85,0 ±20,8 | 0,4 ±23,3 | 0,535 | ||
| Social function | 182 | 88,4 ±18,4 | 182 | 86,3 ±22,1 | -2,1 ±22,8 | 0,299 | ||
| Scales of symptoms/items | ||||||||
| Fatigue | 186 | 15,8 ±17,5 | 186 | 26,4 ±23,0 | -10,6 ±19,9 | <0,001 | ||
| Nausea andvomiting | 186 | 4,5 ±13,8 | 186 | 5,7 ±13,9 | -1,2 ±17,5 | 0,134 | ||
| Pain | 186 | 10,1 ±15,3 | 186 | 19,7 ±23,0 | -9,6 ±21,6 | <0,001 | ||
| Dyspnoea | 182 | 10,3 ±19,0 | 182 | 14,6 ±23,9 | -4,4 ±26,3 | 0,034 | ||
| Insomnia | 184 | 31,7 ±29,8 | 184 | 29,3 ±29,1 | 2,3 ±32,5 | 0,384 | ||
| Loss of appetite | 185 | 14,0 ±21,6 | 185 | 12,2 ±22,4 | 1,8 ±26,4 | 0,408 | ||
| Constipation | 182 | 12,4 ±23,0 | 182 | 15,6 ±23,7 | -3,1 ±27,5 | 0,153 | ||
| Diarrhoea | 182 | 5,7 ±16,4 | 182 | 7,3 ±16,3 | -1,6 ±20,5 | 0,248 | ||
| Financial Concerns | 181 | 5,0 ±16,7 | 181 | 10,7 ±24,5 | -5,7 ±22,7 | 0,001 | ||
| EORTC QLQ Br-23 Breast Cancer Module | ||||||||
| Functional scales | ||||||||
| Body image | 180 | 94,2 ±13,2 | 180 | 85,1 ±23,0 | -9,15 ±22,9 | <0,001 | ||
| Sexual function | 153 | 79,4 ±23,7 | 153 | 80,5 ±21,8 | 1,09 ±21,4 | 0,454 | ||
| Sexual enjoyment | 58 | 55,7 ±32,7 | 58 | 55,2 ±30,3 | -0,57 ±22,1 | 0,841 | ||
| Future perspectives | 179 | 46,0 ±33,5 | 179 | 54,6 ±33,1 | 8,57 ±37,9 | 0,005 | ||
| Scales of symptoms/items | ||||||||
| Adverse effects of systemic therapies | 184 | 14,4 ±13,4 | 184 | 22,7 ±19,6 | -8,36 ±18,9 | <0,001 | ||
| Breast symptoms | 181 | 12,1 ±14,8 | 181 | 23,0 ±19,9 | -10,97 ±20,8 | <0,001 | ||
| Arm symptoms | 181 | 9,2 ±14,5 | 181 | 16,4 ±18,3 | -7,18 ±17,9 | <0,001 | ||
| Worry about hair loss | 29 | 26,4 ±37,1 | 29 | 26,4 ±36,0 | 0 ±46,3 | 0,972 | ||
| State anxiety | 169 | 29,7 ±13,9 | 169 | 19,4 ±11,8 | 10,3 ±14,7 | <0,001 | ||
| Trait anxiety | 165 | 22,1 ±10,5 | 165 | 20,0 ±10,2 | 2,0 ±9,8 | 0,009 | ||
| n (%) | n (%) | |||||||
| Level of state anxiety | 169 | 169 | <0,001 | |||||
| Light | 27 (16,0) | 67 (39,6) | ||||||
| Moderate | 66 (39,1) | 70 (41,4) | ||||||
| Severe | 76 (45,0) | 32 (18,9) | ||||||
| Level of trait anxiety | 165 | 165 | 0,470 | |||||
| Light | 59 (35,8) | 68 (41,2) | ||||||
| Moderate | 81 (49,1) | 74 (44,8) | ||||||
| Severe | 25 (15,2) | 23 (13,9) | ||||||
* SD: Standard Deviation.